Nevro (NYSE: NVRO) reported Q4 EPS of ($0.32), $0.11 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $107.9 million versus the consensus estimate of $107.1 million.

• Revenue for the fourth quarter of 2018 was $107.9 million, a 10% increase compared to $98.0 million during the prior year quarter. U.S. revenue for the fourth quarter of 2018 was $91.6 million, a 13% increase over $81.1 million in the prior year period. International revenue was $16.3 million, compared to $16.9 million in the prior year period, which was a 1% increase on a constant currency basis or a 4% decrease on an as-reported basis. The increase in U.S. revenue was primarily attributable to the continued adoption of the Senza system.
• Gross profit for the fourth quarter of 2018 was $76.2 million compared to $69.5 million in the prior year period. Gross margins were 70.5% in the fourth quarter of 2018 compared to 71.0% in the prior year period.
• Operating expenses for the fourth quarter of 2018 were $84.8 million, an 18% increase compared to $71.7 million in the prior year period. Higher operating expenses were primarily driven by increased headcount and related costs.
• Loss from operations for the fourth quarter of 2018 was $8.6 million compared to $2.2 million for the same period of the prior year.

GUIDANCE:

Nevro sees FY2019 revenue of $400-410 million, versus the consensus of $419.3 million.

For earnings history and earnings-related data on Nevro (NVRO) click here.